title: Intralesional interferon-alpha therapy in advanced malignant melanoma.
abstract: Fifty-one evaluable patients with histologically proven metastatic melanoma and at least one skin metastasis were treated intralesionally with interferon-alpha (IFN-alpha). Twenty-six of the patients were given highly purified natural IFN-alpha 6 Mio. IU three times per week. Twenty-five patients were given 10 Mio. IU three times per week of a recombinant IFN-alpha 2b (rIFN-alpha 2b). All patients were examined for systemic and local responses to this treatment. The systemic responses consisted of nine objective remissions, each of which lasted from 2 to 18 or more months. There were 24 complete or partial local responses. Forty-two of the 51 patients had at least two skin metastases so that IFN-injected and noninjected tumor sites could be compared. The difference between systemic and local efficacy was highly significant statistically (P = 0.0004). The results show that IFN-alpha has clinically observable antitumor activity in malignant melanoma.
authors.affiliation: Department of Medicine and Transfusion, Medizinische Hochschule Hannover, West Germany.
authors.forename: P
authors.initials: P
authors.lastname: von Wussow
authors.forename: B
authors.initials: B
authors.lastname: Block
authors.forename: F
authors.initials: F
authors.lastname: Hartmann
authors.forename: H
authors.initials: H
authors.lastname: Deicher
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000556:secondary / Q000628:therapy
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins